These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 31745161)

  • 21. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
    Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
    Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
    Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
    J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in the application of molecular biomarkers in gliomas.
    Wang J; Su HK; Zhao HF; Chen ZP; To SS
    Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
    Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
    Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
    Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
    Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
    Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas.
    Kramář F; Minárik M; Benešová L; Halková T; Netuka D; Bradáč O; Beneš V
    Folia Biol (Praha); 2016; 62(5):194-202. PubMed ID: 27978414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of Carbohydrate Metabolism and Molecular Genetic Markers in Gliomas with Different Degree of Anaplasia.
    Obukhova LМ; Nikiforova ОN; Kopytova ТV; Orlinskaya NY; Kontorshchikov ММ; Kontorshchikova KN; Medyanik IА; Grishin АS; Vasina DD
    Bull Exp Biol Med; 2021 Nov; 172(1):63-66. PubMed ID: 34791557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting O6-Methylguanine-DNA Methyltransferase Protein Expression in Primary Low- and High-Grade Gliomas Using Certain Qualitative Characteristics of Amide Proton Transfer-Weighted Magnetic Resonance Imaging.
    Su L; Gao P; Lin S; Wu B; Qin W; Lin Y; Xue J
    World Neurosurg; 2018 Aug; 116():e814-e823. PubMed ID: 29803064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
    Gömöri E; Pál J; Kovács B; Dóczi T
    Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas.
    Siegal T
    Adv Tech Stand Neurosurg; 2016; (43):91-108. PubMed ID: 26508407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.
    Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM
    J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninvasive Assessment of O(6)-Methylguanine-DNA Methyltransferase Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space-Occupancy Combined with Structural Magnetic Resonance Imaging.
    He W; Li X; Hua J; Liao S; Guo L; Xiao X; Liu X; Zhou J; Wang W; Xu Y; Wu Y
    J Magn Reson Imaging; 2021 Jul; 54(1):227-236. PubMed ID: 33590929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation.
    Kanekar S; Zacharia BE
    Radiol Clin North Am; 2021 May; 59(3):305-322. PubMed ID: 33926679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.